Abstract:Background: An increase in deaths has been perceived during the pandemic, which cannot be explained only by COVID-19. The actual number of deaths far exceeds the recorded data on deaths directly related to SARS-CoV-2 infection. Data from early and short-lived pandemic studies show a dramatic shift in cardiovascular mortality. Grounded in the post-pandemic era, macroscopic big data on cardiovascular mortality during the pandemic need to be further reviewed and studied, which is crucial for cardiovascular disease prevention and control. Methods: We retrieved and collected data associated with cardiovascular disease mortality from the National Vital Statistic System from the Center for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) platform based on the ICD-10 codes. We applied regression analysis to characterize overall cardiovascular disease mortality trends from 2010 to 2023 and built a time series model to predict mortality for 2020–2023 based on mortality data from 2010 to 2019 in order to affirm the existence of the excess deaths by evaluating observed vs. predicted mortality. We also conducted subgroup analyses by sex, age and race/ethnicity for the purpose of obtaining more specific sociodemographic information. Results: All-cause age-standardised mortality rates (ASMRs) for CVD dramatically increased between 2019 and 2021[annual percentage change (APC) 11.27%, p < 0.01], and then decreased in the following 2021–2023(APC: −7.0%, p < 0.01). Subgroup analyses found that the ASMR change was most pronounced in Alaska Indians/Native American people (APC: 16.5% in 2019–2021, −12.5% in 2021–2023, both p < 0.01), Hispanics (APC: 12.1% in 2019–2021, −12.2% in 2021–2023, both p < 0.05) and non-Hispanic Black people (APC:11.8% in 2019–2021, −10.3% in 2021–2023, both p < 0.01)whether during the increasing or declining phase. Similarly, the ASMR change was particularly dramatic for the 25–44 age group (APC:19.8% in 2019–2021, −15.4% in 2021–2023, both p < 0.01) and males (APC: 11.5% in 2019–2021, −7.6% in 2021–2023, both p < 0.01). By the end of 2023, the proportion of COVID-related excess death remained high among the elderly (22.4%), males (42.8%) and Alaska Indians/Native American people(39.7%). In addition, we did not find the presence of excess deaths in the young (25–44) and middle-aged cohort (45–64) in 2023, while excess deaths remained persistent in the elderly. Conclusions: All-cause ASMRs for CVD increased notably during the initial two years of the COVID-19 pandemic and then witnessed a decline in 2021–2023. The cohorts (the young, males and minorities) with the steepest rise in mortality decreased at the fastest rate instead. Previous initiatives to promote cardiovascular health were effective, but further research on cardiovascular healthcare for the elderly and racial disparities should be attached to priority considering the presence of sociodemographic differences in CVD death.

Long COVID, Non-COVID19 Excess Deaths, and Post-Pandemic Cardiovascular Disease Risks: Mechanistic Links and Intervention Opportunities Mechanistic Links and Intervention Opportunities

Long covid—mechanisms, risk factors, and management

Long COVID: pathophysiological factors and abnormalities of coagulation

Beyond acute infection: molecular mechanisms underpinning cardiovascular complications in long COVID

Biomarkers in long COVID-19: A systematic review

Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics

Impact of the COVID-19 pandemic on cardiovascular mortality and contrast analysis within subgroups

Pathophysiological, immunological, and inflammatory features of long COVID

Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation

Long-term cardiovascular outcomes of COVID-19

Unmasking Pandemic Echoes: An In-Depth Review of Long COVID's Unabated Cardiovascular Consequences beyond 2020

Association of COVID-19 and influenza vaccinations and cardiovascular drugs with hospitalisation and mortality in COVID-19 and Long COVID: 2-year follow-up of 17 million individuals in England

Cardiovascular abnormalities of long-COVID syndrome: Pathogenic basis and potential strategy for treatment and rehabilitation

The Impact of Long COVID-19 on the Cardiovascular System

Long COVID Syndrome and Cardiovascular Manifestations: A Systematic Review and Meta-Analysis

Impact of Long COVID-19 on Health Outcomes Among Adults With Preexisting Cardiovascular Disease and Hypertension: A Systematic Review

Vascular Pathogenesis in Acute and Long COVID: Current Insights and Therapeutic Outlook

LONG-TERM CARDIOVASCULAR EFFECTS OF COVID-19: A COMPARATIVE STUDY

Persistent endotheliopathy in the pathogenesis of long COVID syndrome

Epidemiological and clinical perspectives of long COVID syndrome

The Long-Term Cardiovascular Impact of COVID-19: Pathophysiology, Clinical Manifestations, and Management